Trial Profile
Phase II randomized trial of 3D radiotherapy versus the combination of 3D radiotherapy and erlotinib (Tarceva) in patients with localized-unresectable non-small cell lung cancer non susceptible for chemotherapy treatment
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 27 Feb 2017
Price :
$35
*
At a glance
- Drugs Erlotinib (Primary)
- Indications Non-small cell lung cancer
- Focus Adverse reactions; Therapeutic Use